AM
Therapeutic Areas
Regeneron Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Dupixent (dupilumab) | Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 |
| Odronextamab | Relapsed/Refractory Follicular Lymphoma & DLBCL | Phase 3 |
| Pozelimab | Complement 3 Glomerulopathy (C3G) | Phase 3 |
| Garetosmab | Fibrodysplasia Ossificans Progressiva (FOP) | Phase 3 |
| Linvoseltamab | Relapsed/Refractory Multiple Myeloma | Phase 3 |
| Fianlimab + Cemiplimab | Advanced Melanoma (1L adjuvant) | Phase 3 |
| REGN1908-1909 (Fel d 1 mAb) | Cat Allergy | Phase 3 |
| VEGF C-D | Neovascular Age-Related Macular Degeneration (nAMD) | Phase 2/3 |
Leadership Team at Regeneron
LS
Leonard S. Schleifer
Board Co-Chair, President and Chief Executive Officer
GD
George D. Yancopoulos
Board Co-Chair, President and Chief Scientific Officer
NH
Nouhad Husseini
Senior Vice President, Head of Business Development
MB
Maya Bermingham
Senior Vice President, Public Policy and Government Affairs
ZB
Zoran Berkovic
Senior Vice President, Financial Planning and Analysis
LB
Leonard Brooks
Senior Vice President, Treasurer